Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Saved in:
| Title: | Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer. |
|---|---|
| Authors: | Mizuno K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ku SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Venkadakrishnan VB; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bakht MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sigouros M; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Chan J; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Trigos A; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia., Driskill JH; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Manohar J; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., King A; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA., Presser AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Kim MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Tewari AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Long HW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Quigley D; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Balk S; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Hill S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Mosquera JM; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Einstein D; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. himisha_beltran@dfci.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2025 Jul 01; Vol. 16 (1), pp. 5543. Date of Electronic Publication: 2025 Jul 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-60654-z |
